Prophylaxis for graft portal/splenic venous thrombosis following pancreas transplant varies between institutions. Similarly, treatment of venous thrombosis ranges from early re-exploration to conservative management with anticoagulation. We wished to determine the prevalence of graft splenic vein (SV) thrombosis, as well as the clinical significance of non-occlusive thrombus observed on routine imaging. Records of 112 pancreas transplant recipients over a 5-year period at a single center were reviewed. Venous thrombosis was defined as absence of flow or presence of thrombus identified in any part of the graft SV on ultrasound. Thirty patients (27%) had some degree of thrombus or absence of flow in the SV on postoperative ultrasound. There were 5 graft losses in this group. Four were due to venous thrombosis, and occurred within 20 days of transplant. All patients with non-occlusive partial SV thrombus but normal arterial signal on Doppler ultrasound were successfully treated with IV heparin followed by warfarin for 3-6 months, and remained insulin independent. Findings of arterial signal abnormalities, such as absence or reversal of diastolic flow within the graft, require urgent operative intervention since this finding can be associated with more extensive thrombus that may lead to graft loss.
Prophylaxis for graft portal/splenic venous thrombosis following pancreas transplant varies between institutions. Similarly, treatment of venous thrombosis ranges from early re-exploration to conservative management with anticoagulation. We wished to determine the prevalence of graft splenic vein (SV) thrombosis, as well as the clinical significance of non-occlusive thrombus observed on routine imaging. Records of 112 pancreas transplant recipients over a 5-year period at a single center were reviewed. Venous thrombosis was defined as absence of flow or presence of thrombus identified in any part of the graft SV on ultrasound. Thirty patients (27%) had some degree of thrombus or absence of flow in the SV on postoperative ultrasound. There were 5 graft losses in this group. Four were due to venous thrombosis, and occurred within 20 days of transplant. All patients with non-occlusive partial SV thrombus but normal arterial signal on Doppler ultrasound were successfully treated with IV heparin followed by warfarin for 3-6 months, and remained insulin independent. Findings of arterial signal abnormalities, such as absence or reversal of diastolic flow within the graft, require urgent operative intervention since this finding can be associated with more extensive thrombus that may lead to graft loss.
Introduction
Graft venous thrombosis is a recognized technical complication of pancreas transplantation, estimated to occur in up to 35% of pancreas transplants and accounting for a substantial proportion of early graft loss (1) (2) (3) (4) (5) (6) (7) (8) (9) . Prophylaxis against venous thrombosis varies between institutions (3, (8) (9) (10) (11) , and treatment ranges from urgent re-exploration to conservative management with anticoagulation or aspirin alone (2, 12, 13) . While complete venous thrombosis, typically accompanied by dramatic hyperglycemia, is well recognized and results in graft loss, clinically silent partial thrombosis is less well described with unclear impact on pancreas transplant outcomes. In this study, we aimed to determine the prevalence of graft splenic vein (SV) thrombosis, both complete and partial, and delineate the clinical significance of non-occlusive thrombus observed.
Materials and Methods

Patients and data collection
Doppler ultrasound of the pancreas graft was done routinely on the first post-operative day and additionally as clinically indicated by fever, increased right lower quadrant pain, rising serum amylase (>30% from post-op nadir), and/or elevated serum glucose (rise of 50 mg/dL or any level greater than 200 mg/dL). Venous thrombosis was defined as absence of flow or presence of thrombus identified in any part of the graft SV on ultrasound.
Initial post-operative glucose monitoring was performed every hour for the first 24 h, then every 4 h or prior to meals as diet was advanced. Partial thromboplastin time (PTT) was measured every 6 h during administration of IV heparin. Amylase was measured daily. Following discharge, laboratory assessments were twice weekly until 4 weeks after transplant, then weekly until 8 weeks after transplant, then every other week until 24 weeks after transplant, and monthly thereafter. All patients had at least 4 years of follow-up.
Immunosuppression
Immunosuppression consisted of induction with thymoglobulin and solumedrol (rapid steroid withdrawal in unsensitized recipients), and primary maintenance with tacrolimus and mycophenolate mofetil (MMF).
Anticoagulation
All patients received aspirin (325 mg) prior to surgery, and aspirin (325 mg daily) and dipyridamole (75 mg four times daily) post-operatively. Non-uremic recipients also received a bolus of intravenous (IV) heparin (2000-4000 units, approximately 50 units/kg) at the time of vascular anastomosis and were maintained on prophylactic low dose heparin infusion (200-400 units/hour) for 48-72 h following the transplant. Upon identification of SV thrombus, therapeutic anticoagulation with IV heparin was initiated and titrated to a goal PTT of 40-60 s, with a transition to warfarin for 3-6 months or until documented thrombus resolution. For these recipients, aspirin was maintained but dipyridamole was discontinued.
Statistical analysis
Two-tailed Student's T-test was used to determine statistical significance between means. Fisher's exact test was used to calculate p values when odds ratios or relative risk were used. Log-rank (Mantel-Cox) Test was used to calculate p values for survival curves. GraphPad Prism version 5.03 was used for all calculations.
Results
Prevalence of thrombosis and graft loss There were 112 pancreas transplants performed over the 5-year study period. Thirty patients (27%) had some degree of SV thrombosis identified on post-operative Doppler ultrasound. Representative ultrasound images of partial non-occlusive thrombosis and complete occlusive thrombosis are shown in Figure 1 . Twenty-five patients (22%) had non-occlusive partial SV thrombosis or absence of identifiable flow in the SV with normal graft splenic arterial signal on ultrasound, and five patients (4.5%) had complete occlusive SV thrombus with reversal of diastolic flow on Doppler ultrasound requiring thrombectomy for graft salvage (2 patients) or graft pancreatectomy (3 patients). Demographic data for patients with and without SV thrombus is shown in Table 1 .
Seven recipients with ultrasound findings including graft swelling and abnormal arterial waveforms in the graft splenic artery (absent or reversal of diastolic flow) were taken emergently to the operating room for graft exploration. Two of the seven were found to have a normal-appearing allograft and no identifiable thrombus at exploration. The decision to explore these patients was based in part on the diagnosis of splenic vein thrombosis by the radiologist. Ultrasound reports for these patients stated "the splenic vein is occluded" in one patient, and "the splenic vein is thrombosed" in the second patient. There was "no flow" noted within either graft splenic vein, but both were noted to have "minimal" diastolic flow within the pancreas parenchyma. The first report describes "minimal venous flow within the graft," and the second report states, "there is a trickle of venous flow." In our opinion, these two cases were concerning enough to warrant re-exploration even though there was a small amount of diastolic flow within the graft. Review by a second radiologist determined that the initial findings were misinterpretations, and flow was demonstrated in both grafts. One patient explored on the day of transplantation was found to have a swollen and congested allograft that was salvaged by venous thrombectomy and anticoagulation with IV heparin followed by warfarin. One other recipient had an initially successful venous thrombectomy but lost the graft 19 days later due to thrombosis. Three patients had graft necrosis at the time of exploration requiring transplant pancreatectomy.
In this series the re-exploration rate for suspected graft thrombosis was 6% (7 patients explored out of 112 transplants). The negative laparotomy rate was 29% (2 negative laparotomies out of 7 explorations), and graft salvage rate was 40% (2 successful thrombectomies of 5 complete venous thromboses).
All graft losses due to venous thrombosis occurred within 20 days (1, 4, 7, and 20 days) of transplantation. Graft losses occurred in uremic (2 of 86 SPKs) and non-uremic (1 of 18 PAK; 1 of 8 PTA) recipients. Among the 82 recipients without SV thrombosis, 15 suffered graft loss; all occurred more than 90 days (96-2371 days) after transplantation and were due to causes other than thrombosis (6 secondary to rejection, 8 secondary to patients death, and 1 secondary infected graft pancreatitis). Although complete occlusive SV thrombosis was present in all cases of early graft loss, the presence of any SV thrombus (including nonocclusive thrombus or no identifiable flow within the SV with normal arterial signal on ultrasound and occlusive thrombus with reversal of diastolic flow on ultrasound) was not associated with overall graft loss (OR 1.12, 95% CI 0.32-3.84, p = 1.00) ( Figure 2 ). Moreover, non-occlusive partial SV thrombus did not show an association with rejection (OR 0.93, 95% CI 0.27-3.12, p = 1.00).
Of the 30 recipients with SV thrombosis, 25 patients demonstrated normal arterial signal in spite of nonocclusive partial SV thrombosis. These recipients were successfully treated with IV unfractionated heparin followed by warfarin for 3-6 months (or until documented resolution), and remained insulin independent. Twenty of twenty-five (80%) patients with non-occlusive partial SV thrombus had documented resolution on follow-up ultrasound after anticoagulation. There was no propagation of thrombus in any patient. There was one graft loss in this group due to chronic rejection, which occurred greater than 6 years after transplant. The diagnosis of SV thrombosis was made by Doppler ultrasound in all cases except one. One patient who underwent contrast enhanced CT scan for graft pancreatitis was found to have non-occlusive arterial and venous thrombi. This patient was anticoagulated with IV heparin followed by warfarin and has a functioning graft. CT scan was not used to make or confirm the diagnosis in any other patients. Thrombosis was identified on postoperative day 0-86 (median POD1); 9 on POD0, 10 on POD1, 11 on POD2 or later. The indications for the ultrasound that resulted in the diagnosis of venous thrombosis included routine ultrasound, fever, elevated amylase, elevated glucose, and elevated creatinine ( Table 2 ). There were 268 ultrasounds performed which showed no venous thrombosis. Indications for these negative ultrasounds included routine ultrasound, pain, elevated glucose, fever, elevated amylase, fluid collections, anemia, elevated creatinine, and hernia (Table 2) .
Baseline factors
During the first three post-operative days there was no difference in mean international normalized ratio ( 
Bleeding complications
There was no significant increase in bleeding complications in patients with non-occlusive partial SV thrombus compared to patients without thrombosis (Table 4) . Twenty-four of twenty-five patients with non-occlusive partial SV thrombus were treated with IV unfractionated heparin (titrated to a goal PTT of 40-60 s) in addition to the anti-platelet agents that were administered to all recipients ( Figure 3 ). Twenty-two of twenty-four patients achieved therapeutic levels of anticoagulation (PTT > 40 s). Anticoagulation was stopped in 4 patients due to bleeding. One patient in the non-thrombosis group received full dose IV heparin (goal PTT 40-60 s) due to a Ultrasound findings and association with thrombosis or graft loss Doppler ultrasound findings and graft outcomes for patients found to have graft thrombosis at re-exploration are shown in Table 5 . Abnormal arterial signal with reversal of diastolic flow (OR 22.7, 95% CI 1.12-459, p = 0.009) was associated with occlusive SV thrombus that required re-exploration (complete graft thrombosis or thrombus that required thrombectomy for graft salvage, n = 5) when compared to non-occlusive partial SV thrombus (n = 25). Graft swelling (OR 7.5, 95% CI 0.37-149.7, p = 0.14), and thrombus involving greater than 50% of the splenic vein (OR 8.7, 95% CI 0.44-175, p = 0.13) were also suggestive of complete thrombosis, but did not reach statistical significance.
Discussion
Our findings suggest that, in the absence of arterial signal abnormalities on ultrasound, non-occlusive thrombus in the pancreas graft SV can be successfully treated with anticoagulation. Findings of arterial signal abnormalities on Doppler ultrasound such as absence or reversal of diastolic flow within the graft require urgent operative exploration, since this finding can signal extensive thrombus that may lead to graft loss (14) . This observation may lead to more effective algorithms for the management of this potentially devastating complication.
Venous thrombosis is a feared and common technical complication following pancreas transplant. Currently there is no clear algorithm for its management. Risk factors for the development of graft thrombosis are well described (5) . Measures directed at reducing graft loss due to thrombosis include prophylactic anticoagulation, graft surveillance for early detection, and interventional procedures aimed at graft salvage (9, 15) . The rate of thrombosis in our series of 27%, which included patients with complete or partial SV thrombosis and those observed to have no measurable blood flow within the graft SV on ultrasound, is similar to that in other studies (1-9). Our results have identified findings on Doppler ultrasound that are suggestive of serious complications, and warrant immediate operative exploration. Several patients, however, were discovered to have small amounts of non-occlusive venous thrombus of unclear significance. Our findings show that these patients can be safely managed non-operatively without long-term consequences. We found no overall difference in graft loss between those patients who were identified to have non-occlusive SV thrombus and those who did not. All but one of the graft losses in the group who developed any SV thrombus were due to graft SV thrombosis. Overall rejection rates were also not significantly different between the two groups. Taken together, these findings suggest that partial non-occlusive SV thrombus does not increase the risk of graft loss due to other causes, such as graft pancreatitis or rejection. Graft thrombosis was, however, responsible for all graft losses within the first 90 days, demonstrating the importance of surveillance and prompt intervention for this complication in the early post-operative period.
The optimal use of prophylactic anticoagulants remains a topic of debate. Anticoagulation protocols are center specific, and include a mix of antiplatelet agents, heparin, warfarin, and dextran (3,9,11,16-18). Scheffert et al. (9) demonstrated that low dose anticoagulation with intravenous heparin at a rate of 200-400 units/hour is both safe and may decrease the rate of complete thrombosis. At our center, we routinely use both aspirin and dipyridamole post-operatively, with the addition of low dose intravenous unfractionated heparin in non-uremic recipients. This resulted in a rate of clinically significant SV thrombosis (complete thrombosis that required operative thrombectomy for graft salvage or resulted in graft loss) of 4.5% (5 patients), which is similar to that seen in other studies (0.8-16%) (3, 9, 11, (16) (17) (18) . As a rule, we are very cautious with heparin in the immediate postoperative period, given the high rate of bleeding complications in this population. Another approach that has been proposed is to direct anticoagulation in a patient specific fashion. Vaida et al. proposed thorough evaluation of patients preoperatively for hypercoagulable states using thromboelastography (TEG), with perioperative anticoagulation directed at specific hypercoagulable conditions (18) . One advantage to this approach would be to minimize anticoagulation in patients at lower risk for thrombosis. In the series reported by Vaida, only 1 patient out of 74 transplant recipients (1.4%) required a re-operation for bleeding compared to an overall rate of 5% (6 of 112) in our series, suggesting that this approach may have some benefit in minimizing bleeding complications.
In our series, treatment with therapeutic doses of unfractionated intravenous heparin (titrated to a goal PTT of 40-60 s) did not significantly increase the rate of bleeding complications post-operatively, such as gastrointestinal bleeding or transfusion requirements. This is explained in part by the high rates of bleeding complications experienced in this population at baseline, which was not significantly affected by the addition of intravenous heparin. However, we did find a higher rate of re-operation for bleeding complications in the patients who received therapeutic doses of heparin, suggesting that there may be consequences to therapeutic anticoagulation in this group. The number of re-operations was small (3 patients who received intravenous heparin, 3 patients who did not), however, and the difference did not reach statistical significance. The rate of re-operation for bleeding in our series (5%) was similar to that reported in other series, which ranges from 1-8% (3, 9, 16, 18) .
The protocols for post-operative imaging and surveillance for graft thrombosis vary between institutions. Most centers use a combination of laboratory testing including serum glucose or amylase/lipase, as well as imaging studies to diagnose potential graft thrombosis. MontielCasado et al. demonstrated a correlation between peak post-operative serum amylase and graft venous thrombosis (19) , showing that a peak serum amylase greater than 745 mg/dL in the first 3 days after transplantation was associated with an eightfold greater risk of graft thrombosis. This finding could be used to adjust surveillance imaging protocols in higher risk patients. We did not find this useful in our series, as none of the patients with complete venous thrombosis had a peak serum amylase over 557 U/L. Various imaging studies have been used to evaluate grafts when suspicion of thrombosis arises. Doppler ultrasound, contrast enhanced computed tomography (CT), and magnetic resonance angiography (MRA) all have been used to diagnosis graft thrombosis. However, the contrast nephropathy associated with CT angiography makes ultrasound examination the most desirable modality. This study is operator dependent, however, and examination of the pancreas graft is often difficult due to overlying bowel gas. One patient in our series had non-occlusive thrombus discovered on CT scan performed for pancreatitis, but we do not routinely use CT scan for the evaluation of venous thrombosis. Contrast enhanced Doppler ultrasonography has also been reported (20) . We have recently begun to use contrast enhanced Doppler ultrasonography in our practice, but it was not performed for any patients in this series. This additional technology will likely improve the accuracy of detecting SV thrombosis. Our protocol has evolved to include routine Doppler ultrasound for all pancreas recipients on post-operative day one.
Similarly, the management of graft splenic vein thrombosis varies between institutions. Fridell et al. (13) advocated for early re-exploration in all patients suspected to have significant graft thrombosis. We agree in part with this strategy, as early intervention is important if graft salvage is to be achieved. What is unclear, however, is the threshold for which operative intervention should be performed. At our center, we use serum glucose monitoring and Doppler ultrasound to guide management. Patients found to have significant thrombus burden on ultrasound resulting in arterial signal abnormalities (absent or reversed diastolic flow) underwent immediate reexploration. This strategy resulted in a similar rate of graft salvage as routine early re-exploration (40% in our series vs. 45% with routine early re-exploration), and a lower negative laparotomy rate (20% in our series vs. 43% with routine early re-exploration). There were two patients in our series who were taken to the operating room for graft exploration due to suspected splenic vein thrombosis diagnosed by ultrasound who were found to have normal flow within the graft. The decision to explore these patients was based in part on the diagnosis of splenic vein thrombosis by the radiologist. Interpretation of the ultrasound is operator dependent, however, and on review of these ultrasounds by a senior radiologist, the findings were actually consistent with a normal graft. Based on the relatively high rate of false positive ultrasonographic findings, a confirmatory contrast CT may be indicated prior to returning a pancreas transplant recipient to the operating room.
Endovascular techniques for SV thrombectomy and thrombolysis have also been reported, and have been used to treat pancreas graft venous thrombosis, arterial stenosis, pseudoaneurysms, and arterial-venous malformations (21) (22) (23) . These techniques were not used in our series.
This study is limited by its retrospective design. Additionally, nearly all patients who were thought to have potential partial SV thrombus on imaging without graft compromise were treated with therapeutic doses of unfractionated heparin. This included patients with a finding of "no flow" within the graft SV. For this reason, we are unable to determine the clinical course of these patients if they were to not receive heparin. It is plausible that many of these patients would not require full anticoagulation to prevent graft compromise, but we are unable to comment on this based on our findings.
Conclusion
This study has shown that non-occlusive SV thrombus of the pancreas graft can be managed safely with anticoagulation alone. Ultrasound findings of graft swelling, arterial signal abnormalities such as absent or reversal of diastolic flow, and large thrombus burden warrant emergent operative exploration. Therapeutic anticoagulation with antiplatelet agents in addition to intravenous low molecular weight heparin does not significantly increase the risk of bleeding complications in this patient population.
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